Venkitaraman Ashok R
The Medical Research Council Cancer Cell Unit, Hutchison/MRC Research Centre, Cambridge, UK.
Cancer Cell. 2009 Aug 4;16(2):89-90. doi: 10.1016/j.ccr.2009.07.011.
Targeted therapies exploiting specific molecular defects in cancer cells promise to overcome roadblocks in the development of effective anticancer drugs. A recent report in the New England Journal of Medicine on the early clinical evaluation of Olaparib in cancers lacking the BRCA1 or BRCA2 genes exemplifies this promising new trend.
利用癌细胞中特定分子缺陷的靶向疗法有望克服有效抗癌药物研发中的障碍。《新英格兰医学杂志》最近发表的一篇关于奥拉帕尼在缺乏BRCA1或BRCA2基因的癌症中的早期临床评估报告，例证了这一充满希望的新趋势。
